News Image

Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.

By Mill Chart

Last update: Apr 8, 2024

Our stock screening tool has pinpointed BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) as a growth stock that isn't overvalued. NASDAQ:BMRN is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.

A Closer Look at Growth for NASDAQ:BMRN

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:BMRN has earned a 7 for growth:

  • The Earnings Per Share has grown by an impressive 227.59% over the past year.
  • The Revenue has grown by 15.42% in the past year. This is quite good.
  • The Revenue has been growing by 10.16% on average over the past years. This is quite good.
  • The Earnings Per Share is expected to grow by 49.53% on average over the next years. This is a very strong growth
  • BMRN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.54% yearly.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

Valuation Analysis for NASDAQ:BMRN

ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:BMRN, the assigned 6 reflects its valuation:

  • BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 94.36% of the companies in the same industry.
  • Based on the Price/Forward Earnings ratio, BMRN is valued cheaper than 94.19% of the companies in the same industry.
  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.70% of the companies listed in the same industry.
  • 94.36% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
  • The decent profitability rating of BMRN may justify a higher PE ratio.
  • A more expensive valuation may be justified as BMRN's earnings are expected to grow with 62.29% in the coming years.

A Closer Look at Health for NASDAQ:BMRN

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:BMRN scores a 5 out of 10:

  • An Altman-Z score of 5.82 indicates that BMRN is not in any danger for bankruptcy at the moment.
  • BMRN has a better Altman-Z score (5.82) than 80.00% of its industry peers.
  • The Debt to FCF ratio of BMRN (21.05) is better than 94.36% of its industry peers.
  • BMRN has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • BMRN has a Current Ratio of 2.51. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.

Understanding NASDAQ:BMRN's Profitability

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:BMRN, the assigned 7 is a significant indicator of profitability:

  • The Return On Assets of BMRN (2.45%) is better than 95.04% of its industry peers.
  • Looking at the Return On Equity, with a value of 3.39%, BMRN belongs to the top of the industry, outperforming 95.04% of the companies in the same industry.
  • The Return On Invested Capital of BMRN (2.21%) is better than 94.70% of its industry peers.
  • Looking at the Profit Margin, with a value of 6.93%, BMRN belongs to the top of the industry, outperforming 95.73% of the companies in the same industry.
  • With an excellent Operating Margin value of 6.54%, BMRN belongs to the best of the industry, outperforming 94.87% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 78.72%, BMRN belongs to the top of the industry, outperforming 86.84% of the companies in the same industry.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of BMRN

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (5/21/2024, 7:13:17 PM)

After market: 77.34 0 (0%)

77.34

+0.29 (+0.38%)

BMRN News

News Image22 hours ago - ChartmillNASDAQ:BMRN is not too expensive for the growth it is showing.

Looking for growth without the hefty price tag? Consider BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).

News Image4 days ago - The Motley Fool4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Plain-as-day bargains can still be found, even with the innovation-fueled Nasdaq Composite powering to a fresh all-time high.

News Image13 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in May 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

News Image13 days ago - BusinessInsiderThe 3 Best Biotech Stocks to Buy in May 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We live in the best of times where life is not capped at 45 or 50 years of age,...

News Image17 days ago - BioMarin Pharmaceutical Inc.New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in...

News Image18 days ago - InvestorPlaceCiti Just Cut Its Price Target on These 3 Stocks

Reviewing analyst downgrades may help safeguard investment portfolios amid market uncertainty and Citi price target cuts.

News Image25 days ago - The Motley Fool4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.

News Imagea month ago - InvestorPlace3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition

Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.

News Imagea month ago - InvestorPlaceBMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024

BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Imagea month ago - BusinessInsiderBMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biomarin Pharmaceutical (NASDAQ:BMRN) just reported results for the first quart...

News Imagea month ago - BioMarin Pharmaceutical Inc.BioMarin Reports Record Financial Results for the First Quarter 2024

First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and...

BMRN Links
Follow us for more